OBJECTIVE: To investigate the effect of simultaneous and delayed administration of activated charcoal on the absorption of two verapamil formulations. METHODS: In the first study, 9 healthy volunteers received the following treatments: 1) verapamil 80 mg (conventional formulation) with 50 mL water only, 2) verapamil 80 mg and 25 g activated charcoal immediately afterwards, and 3) verapamil 80 mg with 50 mL water, followed by 25 g charcoal 2 h after verapamil ingestion. In the second study, 8 healthy volunteers received the following treatments: 1) verapamil 240 mg (slow-release formulation) with 50 mL water only, 2) verapamil slow-release 240 mg and 25 g activated charcoal immediately afterwards, 3) verapamil slow-release 240 mg with 50 mL water, followed by 25 g charcoal 2 h after verapamil ingestion, and 4) verapamil slow-release 240 mg with 50 mL water, followed by 25 g charcoal 4 h later. Plasma verapamil concentrations over 24 h were measured by high performance liquid chromatography. RESULTS:Activated charcoal given immediately after the conventional formulation of verapamil reduced the AUC0-24 h by 99% (p < 0.0005) and the Cmax by 98% (p < 0.0005). When the administration of charcoal was delayed 2 h, no significant change in verapamil absorption was observed. With the slow-release formulation of verapamil, charcoal given immediately after verapamil ingestion reduced the verapamil AUC0-24 h by 86% (p = 0.001) and the Cmax by 82% (p = 0.002). When the administration of charcoal was delayed 2 or 4 h, the AUC0-24 h was reduced by 35% (p = 0.04) and 32% (p = 0.001), respectively, but the Cmax was decreased by 13% (p = NS) and 9% (p = NS) only. CONCLUSIONS:Activated charcoal was effective in preventing absorption of verapamil when it was administered immediately after verapamil ingestion. In the case of slow-release formulation, charcoal reduced verapamil absorption by over 30% even when given 4 h after verapamil.
RCT Entities:
OBJECTIVE: To investigate the effect of simultaneous and delayed administration of activated charcoal on the absorption of two verapamil formulations. METHODS: In the first study, 9 healthy volunteers received the following treatments: 1) verapamil 80 mg (conventional formulation) with 50 mL water only, 2) verapamil 80 mg and 25 g activated charcoal immediately afterwards, and 3) verapamil 80 mg with 50 mL water, followed by 25 g charcoal 2 h after verapamil ingestion. In the second study, 8 healthy volunteers received the following treatments: 1) verapamil 240 mg (slow-release formulation) with 50 mL water only, 2) verapamil slow-release 240 mg and 25 g activated charcoal immediately afterwards, 3) verapamil slow-release 240 mg with 50 mL water, followed by 25 g charcoal 2 h after verapamil ingestion, and 4) verapamil slow-release 240 mg with 50 mL water, followed by 25 g charcoal 4 h later. Plasma verapamil concentrations over 24 h were measured by high performance liquid chromatography. RESULTS:Activated charcoal given immediately after the conventional formulation of verapamil reduced the AUC0-24 h by 99% (p < 0.0005) and the Cmax by 98% (p < 0.0005). When the administration of charcoal was delayed 2 h, no significant change in verapamil absorption was observed. With the slow-release formulation of verapamil, charcoal given immediately after verapamil ingestion reduced the verapamil AUC0-24 h by 86% (p = 0.001) and the Cmax by 82% (p = 0.002). When the administration of charcoal was delayed 2 or 4 h, the AUC0-24 h was reduced by 35% (p = 0.04) and 32% (p = 0.001), respectively, but the Cmax was decreased by 13% (p = NS) and 9% (p = NS) only. CONCLUSIONS:Activated charcoal was effective in preventing absorption of verapamil when it was administered immediately after verapamil ingestion. In the case of slow-release formulation, charcoal reduced verapamil absorption by over 30% even when given 4 h after verapamil.
Authors: Maude St-Onge; Kurt Anseeuw; Frank Lee Cantrell; Ian C Gilchrist; Philippe Hantson; Benoit Bailey; Valéry Lavergne; Sophie Gosselin; William Kerns; Martin Laliberté; Eric J Lavonas; David N Juurlink; John Muscedere; Chen-Chang Yang; Tasnim Sinuff; Michael Rieder; Bruno Mégarbane Journal: Crit Care Med Date: 2017-03 Impact factor: 7.598
Authors: Omar A Alshaya; Arwa Alhamed; Sara Althewaibi; Lolwa Fetyani; Shaden Alshehri; Fai Alnashmi; Shmeylan Alharbi; Mohammed Alrashed; Saleh F Alqifari; Abdulrahman I Alshaya Journal: J Multidiscip Healthc Date: 2022-08-30